Home Healthcare Pharmaceuticals Antibody Drug Conjugates Market

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Product Type (Adcetris, Kadcyla, Enhertu, Padcev, Trodelvy, Others), By Application (Blood Cancer, Breast Cancer, Urothelial Cancer, Lung Cancer, Others), By Target (CD33, HER2, CD30, TROP2, Others) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Antibody Drug Conjugates Market, By Product Type 2022-2034 (USD MILLION/ Units)
    1. Adcetris
    2. Kadcyla
    3. Enhertu
    4. Padcev
    5. Trodelvy
    6. Others
  2. Antibody Drug Conjugates Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Blood Cancer
    2. Breast Cancer
    3. Urothelial Cancer
    4. Lung Cancer
    5. Others
  3. Antibody Drug Conjugates Market, By Target 2022-2034 (USD MILLION/ Units)
    1. CD33
    2. HER2
    3. CD30
    4. TROP2
    5. Others
  4. Regional Antibody Drug Conjugates Market
    1. North America
      1. North America Antibody Drug Conjugates Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
      2. North America Antibody Drug Conjugates Market By Application 2022-2034 (USD MILLION/ Units)
        1. Blood Cancer
        2. Breast Cancer
        3. Urothelial Cancer
        4. Lung Cancer
        5. Others
      3. North America Antibody Drug Conjugates Market By Target 2022-2034 (USD MILLION/ Units)
        1. CD33
        2. HER2
        3. CD30
        4. TROP2
        5. Others
      4. U.S.
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      5. Canada
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
    2. Europe
      1. Europe Antibody Drug Conjugates Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
      2. Europe Antibody Drug Conjugates Market By Application 2022-2034 (USD MILLION/ Units)
        1. Blood Cancer
        2. Breast Cancer
        3. Urothelial Cancer
        4. Lung Cancer
        5. Others
      3. Europe Antibody Drug Conjugates Market By Target 2022-2034 (USD MILLION/ Units)
        1. CD33
        2. HER2
        3. CD30
        4. TROP2
        5. Others
      4. U.K.
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      5. Germany
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      6. France
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      7. Spain
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      8. Italy
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      9. Russia
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      10. Nordic
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      11. Benelux
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      12. Rest of Europe
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
    3. APAC
      1. APAC Antibody Drug Conjugates Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
      2. APAC Antibody Drug Conjugates Market By Application 2022-2034 (USD MILLION/ Units)
        1. Blood Cancer
        2. Breast Cancer
        3. Urothelial Cancer
        4. Lung Cancer
        5. Others
      3. APAC Antibody Drug Conjugates Market By Target 2022-2034 (USD MILLION/ Units)
        1. CD33
        2. HER2
        3. CD30
        4. TROP2
        5. Others
      4. China
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      5. Korea
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      6. Japan
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      7. India
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      8. Australia
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      9. Taiwan
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      10. South East Asia
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      11. Rest of Asia-Pacific
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
    4. Middle East and Africa
      1. Middle East and Africa Antibody Drug Conjugates Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
      2. Middle East and Africa Antibody Drug Conjugates Market By Application 2022-2034 (USD MILLION/ Units)
        1. Blood Cancer
        2. Breast Cancer
        3. Urothelial Cancer
        4. Lung Cancer
        5. Others
      3. Middle East and Africa Antibody Drug Conjugates Market By Target 2022-2034 (USD MILLION/ Units)
        1. CD33
        2. HER2
        3. CD30
        4. TROP2
        5. Others
      4. UAE
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      5. Turkey
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      6. Saudi Arabia
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      7. South Africa
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      8. Egypt
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      9. Nigeria
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      10. Rest of MEA
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
    5. LATAM
      1. LATAM Antibody Drug Conjugates Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
      2. LATAM Antibody Drug Conjugates Market By Application 2022-2034 (USD MILLION/ Units)
        1. Blood Cancer
        2. Breast Cancer
        3. Urothelial Cancer
        4. Lung Cancer
        5. Others
      3. LATAM Antibody Drug Conjugates Market By Target 2022-2034 (USD MILLION/ Units)
        1. CD33
        2. HER2
        3. CD30
        4. TROP2
        5. Others
      4. Brazil
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      5. Mexico
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      6. Argentina
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      7. Chile
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      8. Colombia
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
      9. Rest of LATAM
        1. Adcetris
        2. Kadcyla
        3. Enhertu
        4. Padcev
        5. Trodelvy
        6. Others
        7. Blood Cancer
        8. Breast Cancer
        9. Urothelial Cancer
        10. Lung Cancer
        11. Others
        12. CD33
        13. HER2
        14. CD30
        15. TROP2
        16. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.